Parallax Volatility Advisers
KNSA icon

Parallax Volatility Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Parallax Volatility Advisers’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,978
Closed -$107K – 2674
2023
Q1 		$85.8K Buy
+7,978
New +$105K ﹤0.01% 2153
2021
Q3 		– Sell
-16,586
Closed -$231K – 3220
2021
Q2 		$231K Buy
16,586
+10,409
+169% +$158K ﹤0.01% 2424
2021
Q1 		$114K Buy
+6,177
New +$126K ﹤0.01% 2812

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

Parallax Volatility Advisers's KNSA Position: Q2 2023 in Review

Parallax Volatility Advisers sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2023, closing a stake of 7,978 shares — an estimated $107K sold.

Parallax Volatility Advisers first reported a position in KNSA in Q1 2021 and held it in 3 quarters. The position peaked at $231K in Q2 2021. 127 funds tracked by Wall St. Rank hold KNSA as of Q2 2023.

  • Parallax Volatility Advisers reported no remaining Kiniksa Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Parallax Volatility Advisers sold 7,978 Kiniksa Pharmaceuticals shares in Q2 2023, an estimated $107K.
  • Parallax Volatility Advisers first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Parallax Volatility Advisers's Kiniksa Pharmaceuticals position peaked at $231K in Q2 2021.
  • 127 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2023.

Based on Parallax Volatility Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.